VistaGen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Analysts at William Blair issued their Q1 2027 EPS estimates for VistaGen Therapeutics in a research note issued on Wednesday, June 18th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.37) for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for VistaGen Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for VistaGen Therapeutics' Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.48) EPS and Q4 2027 earnings at ($0.41) EPS.
VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its earnings results on Tuesday, June 17th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.09. The business had revenue of ($0.01) million during the quarter, compared to analyst estimates of $0.18 million. VistaGen Therapeutics had a negative return on equity of 58.88% and a negative net margin of 6,777.08%. During the same period in the previous year, the company posted ($0.25) EPS.
VistaGen Therapeutics Stock Performance
Shares of NASDAQ VTGN traded down $0.06 during midday trading on Thursday, hitting $2.00. 389,042 shares of the stock traded hands, compared to its average volume of 174,472. The company has a market cap of $58.32 million, a PE ratio of -1.20 and a beta of 0.70. VistaGen Therapeutics has a one year low of $1.90 and a one year high of $4.21. The business has a 50 day moving average price of $2.31 and a two-hundred day moving average price of $2.56.
Institutional Trading of VistaGen Therapeutics
Hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new stake in VistaGen Therapeutics in the 1st quarter valued at $25,000. Two Sigma Advisers LP bought a new position in VistaGen Therapeutics in the 4th quarter valued at about $35,000. Man Group plc acquired a new position in VistaGen Therapeutics during the 4th quarter valued at about $54,000. Bank of America Corp DE increased its holdings in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock worth $62,000 after purchasing an additional 19,331 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in VistaGen Therapeutics during the 4th quarter worth approximately $66,000. Institutional investors and hedge funds own 78.39% of the company's stock.
About VistaGen Therapeutics
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Read More
Before you consider VistaGen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VistaGen Therapeutics wasn't on the list.
While VistaGen Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
